Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study and Open-Label Extension to Evaluate the Safety and Efficacy of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease (NEULARK)

NCT06680830 is registered in ClinicalTrials.gov with Neuron23 Inc. as lead sponsor.

NCT NCT06680830
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06680830 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study and Open-Label Extension to Evaluate the Safety and Efficacy of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease (NEULARK)
Lead sponsor
Neuron23 Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
January 17, 2025
Completion date
June 30, 2028
Enrollment
150 (estimated)
Sites
72

Conditions

As the registry lists them; a condition with its own page is linked.

early parkinson disease (early pd), idiopathic parkinson disease, parkinson, parkinson disease, parkinson disease, idiopathic